Vaccinex Stock Forecast, Price & News

Vaccinex (NASDAQ:VCNX) Frequently Asked Questions

What stocks does MarketBeat like better than Vaccinex?

Wall Street analysts have given Vaccinex a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vaccinex wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Vaccinex?

Vaccinex saw a decrease in short interest in the month of August. As of August 13th, there was short interest totaling 714,900 shares, a decrease of 20.8% from the July 29th total of 902,100 shares. Based on an average daily volume of 417,500 shares, the days-to-cover ratio is currently 1.7 days. Approximately 5.2% of the company's shares are short sold.
View Vaccinex's Short Interest.

When is Vaccinex's next earnings date?

Vaccinex is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for Vaccinex.

How were Vaccinex's earnings last quarter?

Vaccinex, Inc. (NASDAQ:VCNX) announced its quarterly earnings data on Monday, August, 16th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.29) by $0.08.
View Vaccinex's earnings history.

How has Vaccinex's stock price been impacted by COVID-19?

Vaccinex's stock was trading at $4.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VCNX shares have decreased by 48.2% and is now trading at $2.16.
View which stocks have been most impacted by COVID-19.

Who are Vaccinex's key executives?

Vaccinex's management team includes the following people:

• Maurice Zauderer, President, Chief Executive Officer & Director
• Elizabeth Evans, Chief Operating Officer
• Scott E. Royer, Chief Financial & Accounting Officer
• Ernie Smith, Chief Scientific Officer & Senior VP-Research
• John E. Leonard, Senior Vice President-Development

Who are some of Vaccinex's key competitors?

Some companies that are related to Vaccinex include Flora Growth (FLGC), CymaBay Therapeutics (CBAY), Avalo Therapeutics (AVTX), Adicet Bio (ACET), Sernova (SEOVF), Seelos Therapeutics (SEEL), Paratek Pharmaceuticals (PRTK), Frequency Therapeutics (FREQ), Immunic (IMUX), Harrow Health (HROW), iBio (IBIO), Mustang Bio (MBIO), Oncorus (ONCR), Atreca (BCEL) and Adamas Pharmaceuticals (ADMS).
View all of VCNX's competitors.

What other stocks do shareholders of Vaccinex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), Cerecor (CERC), Exelixis (EXEL), Pfizer (PFE), AVEO Pharmaceuticals (AVEO), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

When did Vaccinex IPO?

(VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

What is Vaccinex's stock symbol?

Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."

Who are Vaccinex's major shareholders?

Vaccinex's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.11%), Point72 Asset Management L.P. (1.39%), Telemetry Investments L.L.C. (0.42%), Geode Capital Management LLC (0.37%), State Street Corp (0.24%) and Simplex Trading LLC (0.00%). Company insiders that own Vaccinex stock include Albert Friedberg and Maurice Zauderer.
View institutional ownership trends for Vaccinex.

Which institutional investors are selling Vaccinex stock?

VCNX stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP.
View insider buying and selling activity for Vaccinex or view top insider-selling stocks.

Which institutional investors are buying Vaccinex stock?

VCNX stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Vanguard Group Inc., State Street Corp, Simplex Trading LLC, Geode Capital Management LLC, Virtu Financial LLC, Telemetry Investments L.L.C., and HAP Trading LLC. Company insiders that have bought Vaccinex stock in the last two years include Albert Friedberg, and Maurice Zauderer.
View insider buying and selling activity for Vaccinex or or view top insider-buying stocks.

How do I buy shares of Vaccinex?

Shares of VCNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaccinex's stock price today?

One share of VCNX stock can currently be purchased for approximately $2.16.

How much money does Vaccinex make?

Vaccinex has a market capitalization of $66.53 million and generates $630,000.00 in revenue each year.

How many employees does Vaccinex have?

Vaccinex employs 40 workers across the globe.

What is Vaccinex's official website?

The official website for Vaccinex is www.vaccinex.com.

Where are Vaccinex's headquarters?

Vaccinex is headquartered at 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620.

How can I contact Vaccinex?

Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The company can be reached via phone at (585) 271-2700 or via email at [email protected].